Use of Bevacizumab as a First-Line Treatment for Metastatic Breast Cancer

Manso, Luís; Cuadro, Fernando Moreno; Marquez, Raul; Castelo, Beatriz; Arcediano, Alberto; Arroyo, Marta Marina; Ballesteros, Ana Isabel; Calvo, Isabel; Echarri, María J.; Enrech, Santos; Gómez, Amalia; Val, Ricardo González del; López-Miranda, Elena; Martin-Angulo, M.; Martínez-Jáñez, Noelia; Olier, C; Zamora, Pilar

doi:10.3747/co.22.2210

Cited by 16 publications

(14 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bevacizumab is also effective in the treatment of metastatic cervical cancer in combination with chemotherapy, such as cisplatin and paclitaxel, which increases the OS of patients [54]. Although bevacizumab was removed by the FDA for the treatment of metastatic breast cancer, citing safety concerns, the clinical data show that bevacizumab treatment significantly prolongs PFS of metastatic breast cancer patients with an acceptable toxicity profile and is still advised for application in the clinic [55,56].…”

Section: Monoclonal Antibody Therapymentioning

confidence: 99%

The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis

Yong

et al. 2019

Cells

View full text Add to dashboard Cite

Tumor vessels provide essential paths for tumor cells to escape from the primary tumor and form metastatic foci in distant organs. The vessel targeting strategy has been widely used as an important clinical cancer chemotherapeutic strategy for patients with metastatic tumors. Our review introduces the contribution of angiogenesis to tumor metastasis and summarizes the application of Food and Drug Administration (FDA)-approved vessel targeting drugs for metastatic tumors. We recommend the application and mechanisms of vascular targeting drugs for inhibiting tumor metastasis and discuss the risk and corresponding countermeasures after vessel targeting treatment.

show abstract

Section: Monoclonal Antibody Therapymentioning

confidence: 99%

The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis

Yong

et al. 2019

Cells

View full text Add to dashboard Cite

show abstract

“…As a matter of fact, bevacizumab, the first anti-VEGF agent approved in the treatment of cancer, has demonstrated efficacy in breast cancer in combination with paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer, after results of the E2100 randomized phase 3 clinical trial [5]. The benefit was particularly significant for triple-negative breast cancer with substantial improvement as regards median progression-free survival (PFS) and overall response rate [6, 7]. The risk of progression was reduced by more than half, with minimal toxic effects and no detrimental effect on overall quality of life.…”

Section: Introductionmentioning

confidence: 99%

Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study

et al. 2019

View full text Add to dashboard Cite

Background: Triple-negative breast cancer remains a disease with poor prognosis and few treatment options, due to the lack of therapeutic targets. Bevacizumab, the first anti-VEGF agent approved in the treatment of cancer, has demonstrated efficacy in breast cancer in combination with paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer. Despite the fact that the benefit was particularly significant for triple-negative breast cancer with its approval in 2008 by the FDA, this decision was later reversed as there was no improvement in overall survival in addition to significant costs. Objectives: The scope of the present study is to focus on the role of bevacizumab in triple-negative breast cancer through the analysis of overall survival, progression-free survival, and cost benefit among 45 patients in a French monocentric study and to discuss new paradigms of endpoints. Methods: All patients diagnosed with metastatic triple-negative breast cancer, for whom first-line treatment was bevacizumab in combination with paclitaxel between January 2011 and April 2018 were included in this single-center retrospective study, and a chart review of all recruited subjects was performed from medical records. Results: In this real-life study among 45 patients with metastatic triple-negative breast cancer, bevacizumab provided a significant benefit for a category of patients, with longer median progression-free survival and the ability of maintenance therapy associated to limited side effects. Conclusions: Beyond being the phoenix of breast oncology and a magnet of controversy, the case of bevacizumab in metastatic breast cancer highlights one of the greatest challenges in oncology, namely to balance modest clinical benefits with exponential costs. A balance needs to be found between health care affordability, high price of progress, and the best medical decision for the patients, in order to avoid the “unbreathable tipping point” we are actually dealing with.

show abstract

“…Its efficacy has been also demonstrated in an in vitro model of pNETs (26). Bevacizumab showed anti-tumor activity and efficacy both in monotherapy and in combination with interferon in metastatic renal cell carcinoma (27) or chemotherapy in metastatic colorectal cancer (28), lung (29) and breast (30) cancer, thus obtaining the approval by pharmaceutical authorities.…”

Section: Angiogenesis Inhibitors To Treat Pnetsmentioning

confidence: 99%

Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors

Capozzi

Arx

Divitiis

et al. 2016

View full text Add to dashboard Cite

Abstract. In recent years, many progresses have been pursued in the management of advanced pancreatic neuroendocrine tumor (pNET); most of them were prompted by increasing knowledge of biology of these neoplasms, including the identification of promisingEpidemiological studies showed that pancreatic neuroendocrine tumors (pNETs) are rare cancers with an incidence of less than 1 per 100,000 persons per year, representing 1-2% of all pancreatic neoplasms in Europe (1). However, in recent years, an increase of pNETs' incidence has been registered probably because of a better identification of these tumors due to the improvement of pathologic and diagnostic techniques (2). It is fundamental, in order to indicate the most appropriate therapy, a clear identification of the pNETs' origin, grading, as well as presence and localization of metastases. To date, this is possible by acquiring data from laboratory tests, histology and radiologic imaging (3, 4). Biopsy of the tumor is the first fundamental step to achieve an appropriate diagnosis and classification of pNET, including immunocytochemical staining to determine eventual secretion of substances ("secreting" pNETs). Thus, the first important discrimination is between well-differentiated (low or intermediate grade) or poorly differentiated (high-grade) tumors (6).On a clinical point of view, some types of pNETs are asymptomatic and indolent and may grow at a very low rate for several years before displaying symptoms; other types can rapidly progress determining disability and worsening of quality of life (7).If the tumor is identified in early, localized stage, radical surgery is the gold standard treatment (8). Unfortunately, hepatic 5025 This article is freely accessible online.

show abstract

Use of Bevacizumab as a First-Line Treatment for Metastatic Breast Cancer

Cited by 16 publications

References 43 publications

The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis

The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis

Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study

Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors

Contact Info

Product

Resources

About